Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children

血栓性微血管病 伊库利珠单抗 医学 降纤酶 耐火材料(行星科学) 补体系统 内科学 造血干细胞移植 钙调神经磷酸酶 移植 非典型溶血尿毒综合征 胃肠病学 免疫学 抗体 物理 疾病 天体生物学
作者
Michelle Long Schoettler,Seema R. Patel,Elyse Bryson,Laura Deeb,Benjamin Watkins,Muna Qayed,Shanmuganathan Chandrakasan,Taylor Fitch,Katherine Silvis,Jayre A Jones,Satheesh Chonat,Kirsten M. Williams
标识
DOI:10.1016/j.jtct.2023.12.017
摘要

Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and potentially severe complication of hematopoietic cell transplantation. TA-TMA-directed therapy with eculizumab, a complement C5 inhibitor, has resulted in a survival benefit in some studies. However, children with TA-TMA refractory to C5 inhibition with eculizumab (rTA-TMA) have mortality rates exceeding 80%, and there are no other known therapies. Narsoplimab, an inhibitor of the MASP-2 effector enzyme of the lectin pathway, has been studied in adults with TA-TMA as first-line therapy with a response rate of 61%. Although there are limited data on narsoplimab use as a second-line agent in children, we hypothesized, that complement pathways proximal to C5 are activated in rTA-TMA, and that narsoplimab may ameliorate rTA-TMA in children. In this single-center study, children were enrolled on single-patient, Institutional Review Board-approved compassionate use protocols for narsoplimab treatment. Clinical complement lab tests were obtained at the discretion of the treating physician, although all patients were also offered participation in a companion biomarker study. Research blood samples were obtained at the time of TA-TMA diagnosis, prior to eculizumab treatment, at the time of refractory TA-TMA diagnosis prior to the first narsoplimab dose, and 2 weeks after the first narsoplimab dose. Single ELISA kits were used to measure markers of complement activation according to the manufacture's instructions. Five children with rTA-TMA received narsoplimab; 3 were in multiorgan failure and 2 had worsening multiorgan dysfunction at the time of treatment. Additional comorbidities at the time of treatment included sinusoidal obstructive syndrome (SOS; n = 3), viral infection (n = 3), and steroid-refractory stage 4 lower gut grade IV acute graft-versus-host disease (aGVHD, n = 3). Two infants with concurrent SOS and no aGVHD had resolution of organ dysfunction; 1 also developed transfusion-independence (complete response), and the other's hematologic response was not assessable in the setting of leukemia and chemotherapy (partial response). One additional patient achieved transfusion independence but had no improvement in organ manifestations (partial response), and 2 patients treated late in the course of disease had no response. Narsoplimab was well tolerated without any attributed adverse effects. Three patients consented to provide additional research blood samples. One patient with resolution of organ failure demonstrated evidence of proximal pathway activation prior to narsoplimab treatment with subsequent declines in Ba, Bb, C3a, and C5a and increases in C3 in both clinical and research lab tests. Otherwise, there was no clear pattern of other complement markers, including MASP-2 levels, after therapy. In this cohort of ill children with rTA-TMA and multiple comorbidities, 3 patients benefited from narsoplimab. Notably, the 2 patients with resolution of organ involvement did not have steroid-refractory aGVHD, which is thought to be a critical driver of TA-TMA. Additional studies are needed to determine which patients are most likely to benefit from narsoplimab and which markers may be most helpful for monitoring lectin pathway activation and inhibition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
物理苟完成签到,获得积分10
1秒前
大力信封发布了新的文献求助10
1秒前
1秒前
元谷雪完成签到,获得积分10
2秒前
2秒前
3秒前
yiren发布了新的文献求助10
3秒前
LEE完成签到,获得积分10
3秒前
田様应助清新的冰凡采纳,获得10
3秒前
maybe完成签到,获得积分10
3秒前
dypdyp应助飞云采纳,获得10
4秒前
Dritsw应助超爱蛋炒饭采纳,获得10
4秒前
326361887完成签到,获得积分20
6秒前
吴昱晟发布了新的文献求助30
6秒前
崛起之邦完成签到,获得积分10
7秒前
学术的刘完成签到,获得积分10
7秒前
WPY完成签到,获得积分10
7秒前
无名发布了新的文献求助10
8秒前
可可发布了新的文献求助10
8秒前
小熊发布了新的文献求助10
8秒前
早安发布了新的文献求助10
10秒前
古拉桑发布了新的文献求助30
10秒前
大剑日太刀完成签到,获得积分10
11秒前
万能图书馆应助silvery采纳,获得10
11秒前
11秒前
13秒前
Cashwa完成签到,获得积分10
14秒前
14秒前
务实蜻蜓完成签到,获得积分10
14秒前
上官若男应助无名采纳,获得10
14秒前
小熊完成签到,获得积分20
14秒前
王小贝完成签到,获得积分10
14秒前
崛起之邦发布了新的文献求助10
15秒前
1351567822应助wang采纳,获得10
15秒前
YamDaamCaa应助cxzdm采纳,获得30
16秒前
16秒前
garey完成签到,获得积分20
16秒前
调皮铸海完成签到,获得积分10
16秒前
早安完成签到,获得积分10
18秒前
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970120
求助须知:如何正确求助?哪些是违规求助? 3514810
关于积分的说明 11176124
捐赠科研通 3250136
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875647
科研通“疑难数据库(出版商)”最低求助积分说明 804964